CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...